

In the claims:

1. (Currently amended) A method for therapeutically treating a mammal bearing a tumor, the method comprising generating an immune response by administering to the mammal an effective amount of a therapeutic composition consisting essentially of Alt-1 an antibody or antigen binding fragment thereof that binds to an epitope of MUC-1, said epitope being an epitope to which a monoclonal antibody produced by a hybridoma that has ATCC Designation Number PTA-975 specifically binds. ~~wherein the mammal generates an immune response that comprises an antibody that specifically binds to an epitope of tumor associated MUC1 that is different from the epitope of tumor associated MUC-1 that is specifically bound by Alt-1.~~
2. (Currently amended) The method of claim 1, wherein the antibody or fragment thereof that binds to an epitope of MUC-1 ~~the binding agent~~ is non-radiolabeled.
- 3-4. (Cancelled)
5. (Currently amended) The method of claim 1, wherein the immune response ~~also~~ includes a T cell response.
6. (Original) The method of claim 1, wherein the mammal is a human.
7. (Currently amended) The method of claim 1, wherein ~~Alt-1~~ the therapeutic composition is administered intravenously.
8. (Currently amended) The method of claim 1, wherein ~~Alt-1~~ the therapeutic composition is administered subcutaneously.
9. (Currently amended) The method of claim 1, wherein the binding agent antibody or antigen binding fragment thereof in the therapeutic composition is administered at a dosage of less than 8 mg / 30kg body weight.

10. **(Currently amended)** The method of claim 1, wherein the binding agent antibody or antigen binding fragment in the therapeutic composition is administered at a dosage of less than 3 mg / 30kg body weight.

11. **(Currently amended)** The method of claim 1, wherein the binding agent antibody or antigen binding fragment in the therapeutic composition is administered at a dosage of about 2 mg / patient.

12-15. **(Cancelled)**

16. **(Currently amended)** A method for therapeutically treating a mammal bearing a tumor, the method inducing the production of antibodies against a multi-epitopic antigen comprising administering to the mammal an effective amount of a therapeutic composition consisting essentially of a binding agent antibody or antigen binding fragment thereof that specifically binds to a first epitope on the multi-epitopic antigen ~~epitope of tumor associated MUC-1~~, wherein such that the mammal generates an immune response against a second epitope on the antigen, wherein the antigen is MUC-1 and the first epitope is an epitope of MUC-1 to which a monoclonal antibody produced by a hybridoma that has ATCC Designation Number PTA-975 specifically binds, that comprises an antibody that specifically binds to an epitope of tumor associated MUC1 that is different from the epitope of tumor associated MUC1 that is specifically bound by the binding agent.

17. **(Currently amended)** The method of claim 16, wherein the binding agent antibody or antigen binding fragment thereof is non-radiolabeled.

18. **(Currently amended)** The method of claim 16, A method for therapeutically treating a mammal bearing a tumor comprising administering to the mammal an effective amount of a therapeutic composition consisting essentially of an antibody or antigen binding fragment thereof that specifically binds to a first epitope on the multi-epitopic antigen MUC-1 such that the mammal generates an immune response against a second epitope on the antigen, wherein the binding agent antibody is not a monoclonal antibody selected from: HMPV, VU-3-C6, MF06,

VU-11-D1, MF30, BCP8, DF3, BC2, B27.29, VU-3-D1, 7540MR, MF11, Bc4E549, VU-11-E2, M38, E29, GP1.4, 214D4, BC4W154, HMFG-2, HMFG-1, C595, Mc5 and A76-A/C7.

19-20. **(Cancelled)**

21. **(Currently amended)** The method of claim 19 or 18, wherein the immune response also includes a T cell response.
22. **(Currently amended)** The method of claim 16 or 18, wherein the binding agent antibody is Alt-1.
23. **(Currently amended)** The method of claim 16 or 18, wherein the mammal is a human.
24. **(Cancelled)**
25. **(Currently amended)** The method of claim 16 or 18, wherein the therapeutic composition binding agent is administered intravenously.
26. **(Currently amended)** The method of claim 16 or 18, wherein the therapeutic composition binding agent is administered subcutaneously.
27. **(Currently amended)** The method of claim 16 or 18, wherein the binding agent antibody or antigen binding fragment thereof in the therapeutic composition is administered at a dosage of less than 8 mg / 30kg body weight.
28. **(Currently amended)** The method of claim 16 or 18, wherein the binding agent antibody or antigen binding fragment thereof in the therapeutic composition is administered at a dosage of less than 3 mg / 30kg body weight.
29. **(Currently amended)** The method of claim 16 or 18, wherein the binding agent antibody or antigen binding fragment thereof in the therapeutic composition is administered at a dosage of about 2 mg / patient.

30-32. (Cancelled)

33. (Currently amended) ~~The therapeutic composition according to claim 36, A therapeutic composition consisting essentially of an antibody or antigen binding fragment thereof that specifically binds to both soluble and tumor-bound tumor-associated MUC-1 and that is effective in therapeutically treating a mammal having a tumor that expresses a tumor-associated MUC-1, wherein the binding agent antibody is not a monoclonal antibody selected from: HMPV, VU-3-C6, MF06, VU-11-D1, MF30, BCP8, DF3, BC2, B27.29, VU-3-D1, 7540MR, MF11, Bc4E549, VU-11-E2, M38, E29, GP1.4, 214D4, BC4W154, HMFG-2, HMFG1, C595, Mc5 and A76-A/C7.~~

34-41. (Cancelled)

42. (New) The method of claim 16 or 18, wherein the antibody or antigen binding fragment thereof is selected from a monoclonal antibody, a chimeric antibody, a genetically engineered antibody, a Fab fragment, a F(ab')₂ fragment, and a single chain antibody.

43. (New) The method of claim 1 wherein the antibody is Alt-1.

44. (New) The method of claim 1 wherein the epitope consists of the carbohydrate and peptide amino acid sequence DTRPAP (SEQ ID No. 5).

45. (New) The method of claim 16, wherein the first epitope consists of the carbohydrate and peptide amino acid sequence DTRPAP (SEQ ID No. 5).

46. (New) The method of claim 18, wherein the first epitope consists of the carbohydrate and peptide amino acid sequence DTRPAP (SEQ ID No. 5).

47. (New) The method of claim 18, wherein the antibody or antigen binding fragment thereof is non-radiolabeled.

48. (New) The therapeutic composition of claim 33, wherein the antibody or antigen binding fragment thereof is non-radiolabeled.